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Abstract This study reports plasma levels of a specific non- 
enzymatic peroxidation product of arachidonic acid, esterified 
8-epi-PGF2~, from healthy- and NIDDM individuals as an index 
of oxidative stress in vivo. Plasma 8-epi-PGF2,~ was isolated by 
solid-phase xtraction on a C~s followed by an NH2 cartridge and 
analyzed by GC-MS/NICI as PFB-ester/TMS-ether derivative. 
We found that the average concentration of esterified 8-epi- 
PGF2~ among NIDDM subjects (0.93 + 0.07 riM, n = 39) was 
higher (P < 0.0001, Mann-Whitney test) than in healthy individ- 
uals (0.28 + 0.04 nM, n = 15). These data indicate that NIDDM 
is associated with increased plasma lipid peroxidation. 
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I. Introduction 
F2-isoprostanes consists of a series of prostaglandin F2-1ike 
compounds formed during peroxidation of arachidonic acid by 
a mechanism independent of the cyclooxgenase pathway [1]. In 
theory, F2-isoprostanes can be grouped into four subtypes (Fig. 
1). Of these, 8-epi-PGF2~ has received considerable attention 
because of its role as a pharmacological mediator in vivo [2]. 
Elevated plasma levels of 8-epi-PGF2~ have been reported in 
two animal models of free radical injury and lipid peroxidation 
[1,3]. Information in the literature concerning the levels of 8- 
epi-PGF2~ in human plasma, however, is l imited. Morrow et 
al. [1] reported the presence of0.01~0.11 nM of presumably free 
(unesterified) 8-epi-PGF2= in plasma from healthy donors 
(n = 5). Their estimation was downgraded to 0.05 + 0.02 nM in 
a recent publication [4]. Lynch et al. [5] detected 0.02 nM and 
0.10 nM of free and esterified F2-isoprostanes , respectively, in 
plasma from a normolipidemic ndividual. The 8-epi-PGF2~ is 
initially formed esterified to phospholipids and then released by 
the action of a phospholipase to become biologically active [6]. 
We have recently developed a rapid and reliable SPE/GC-MS 
assay for the measurement of plasma 8-epi-PGF2~, a specific 
non-enzymatic peroxidation product of arachidonic acid [7]. In 
this study, we: (a) investigated the influence of cyclooxygenase 
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inhibitors on the formation of 8-epi-PGF2~ in plasma, both in 
vivo and ex vivo; and (b) analysed plasma from healthy and 
N IDDM individuals for the content of free (unesterified) as 
well as total (sum of free and esterified) 8-epi-PGF2~ as an index 
of oxidative stress in vivo. 
2. Materials and methods 
2.1. Materials 
Prostaglandin F2(9,11,15-trihydroxy-5,11-eicosadienoic acid) stand- 
ards including 9~,1 lc~-, 9~,1 lfl-, 9fl,11~-, 8-epi- and 3,3',4,4'-tetradeu- 
terated 9a, 11 c~-PGF2 (PGF2-d4) were obtained from Cascade Biochem 
(Reading, UK). Sep-Pak C18 (500 mg) cartridges were obtained from 
Millipore Inc. (Millford, MA, USA). Aminopropyl (NH2) cartridges 
(Supelclean LC-NH> 500 rag) were supplied by Supelco (Bellefonte, 
PA, USA), BSTFA was purchased from Pierce Chemical Co. (Rock- 
ford, IL, USA). Indomethacin, BHT, PFB and DIPEA were obtained 
from Sigma Chemical Co. (St. Louis, MO, USA). All commercially 
available chemicals and reagents were of analytical grade or greater 
purity. 
2.2. Subjects 
Individuals with NIDDM (n = 39) were recruited from the Univer- 
sity College London Hospital (UCL) outpatient clinic services. The 
control group comprised of 15 healthy volunteers from the staff of the 
department ofMedicine, UCL. An additional group of healthy volun- 
teers (n = 6) from the staff of UCL was used to study the effect of 
cyclooxygenase inhibitors on plasma 8-epi-PGF2~ levels. 
2.3. Sample collection and plasma preparation 
(a) Effect of cyclooxygenase inhibition on plasma levels of 8-epi- 
PGFe~. Aspirin and indomethacin were used to study cyclooxygenase 
inhibition in vivo and ex vivo, respectively. For the in vivo study, blood 
(20 ml) was collected in 3.8% trisodium citrate (blood/anticoagulant 
ratio 9: 1) before and after administration f three doses of 600 mg 
aspirin (12, 4 and 2 h prior to sample collection). Platelet-poor plasma 
was prepared by centrifugation at 2400 x g at 4°C for 15 min. Aliquots 
(1 ml) of the plasma samples were transferred to Eppendorf tubes and 
BHT was added (final concentration 20/.tM) as a chain breaking anti- 
oxidant. The samples were then stored at -70°C and analysed within 
2 weeks. For the evaluation of ex vivo generation of 8-epi-PGF2~, 
indomethacin in 5% sodium bicarbonate was added to the blood sam- 
ples immediately after collection (final concentration 14pM). The sam- 
ples were allowed to stand for 45 min at 4°C to achieve complete 
inhibition of the cyclooxgenase enzymes. Platelet-poor plasma was then 
isolated and stored as described above. 
(b) Measurement of 8-epi-PGFe~ as an index of oxidative stress. Blood 
(10 ml) was drawn from control and NIDDM subjects into lithium 
heparin Vacutainers. Platelet-poor plasma was obtained by centrifuga- 
tion (as above) and aliquots of the plasma (1 ml) were transferred to 
Eppendorf tubes and stored at -70°C until analysis. 
2.4. Clinical measurements 
Analysis of plasma triglycerides, total cholesterol, fasting glucose 
and glycosylated haemoglobin A (HbAlc) were carried out at the UCL 
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Fig. 1. Formation of F2-isoprostane regio-isomers during non-enzymatic peroxidation of arachidonic acid. Regio-isomer IV represent the 8-epi-PGF 2
stereo-isomers. 
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Hospital blood analysis laboratory. Clinical data for the control and 
patient groups are listed in Table 1. 
2.5. Solid-phase xtraction procedure 
(a) Free (non-esterified) F2-isoprostanes. Plasma (1 ml) was spiked 
with PGF2-d4 (5 ng in 50 121 ethanol) as the internal standard. The 
sample was acidified using 2 ml of water (pH 3.0) and allowed to 
equilibrate at 4°C for 15 min. The sample was then applied to a C18 
cartridge (500 mg) preconditioned with methanol and water (pH 3.0). 
The cartridge was sequentially washed with 10 ml of water (pH 3.0) and 
acetonitrile/water (15:85, v/v) to remove polar materials. Lipids were 
eluted by washing the cartridge with 5 ml of hexane/ethyl acetate/ 
propan-2-ol (30:65:5, v/v). This eluate was then applied to an NH2 
cartridge (500 mg), preconditioned with hexane (5 ml). The NH2 car- 
tridge was sequentially washed with 10 ml of hexane/ethyl acetate 
(30:70, v/v), acetonitrile/water (9: 1, v/v) and acetonitrile. Fz-iso- 
prostanes were eluted from the NH2 cartridge with 5 ml of ethyl acetate/ 
methanol/acetic acid (10: 85 : 5, v/v). The sample was immediately trans- 
ferred into a screw-cap vial and the solvent was evaporated under 
nitrogen at room temperature. 
(b) Total (sum of free and esterified) F2-isoprostanes . Plasma (1 ml) 
was incubated with 1 ml of an aqueous olution of potassium hydroxide 
(1.0 M) at 40°C for 30 rain to hydrolyse sterified F2-isoprostanes. 
Thereafter, water (1 ml) was added and the pH was adjusted to 3.0 using 
concentrated HC1. PGF2-d4 (5 ng in 50 121 ethanol) was added as an 
internal standard and the sample was centrifuged at 2400 x g for 5 min. 
The supernatant was removed and applied to the solid-phase extraction 
procedure as described above. 
2.6. Derivatization 
The PFB-ester was prepared by adding 40 121 of PFB (10% in acetoni- 
trile) and 20 121 of DIPEA (10% in acetonitrile) to the dried eluate 
following SPE. The vial was sealed with a Teflon-lined cap and was 
incubated at 40°C for 45 min. The solvent was then removed under a 
stream of nitrogen. TMS-ethers were prepared by incubation of the 
dried sample with 50 121 BSTFA and 5 121 DIPEA (10% in acetonitrile) 
at 4°C overnight. After removing excess solvent with nitrogen, the 
derivatised sample was reconstituted in &o-octane (40 121) containing 
10% BSTFA and was analysed immediately by GC-MS. 
2.7. Gas chromatography-mass spectrometry 
GC-MS/NICI analysis was carried out using a Hewlett Packard 5890 
GC (Bracknell, UK) linked to a VG70SEQ MS (Fisons Instruments, 
Manchester, UK), using ammonia s reagent gas. F2-isoprostanes were 
separated on an SPB-1701 column (30 m x 0.25 mm i.d. x 0.25 12m D r, 
Supelco, PA, USA). Samples (2/21) were injected automatically into a 
temperature programmed Gerstel injector (Thames Chromatography, 
Maidenhead, UK). The GC oven was programmed from 175 to 270°C 
at a rate of 30°C/min. Quantitative analysis was performed using se- 
lected ion monitoring (SIM) of the carboxylate anion [M-181]- at rn/z 
569 for the Fz-isoprostanes and mlz 573 for PGF2-d4. 
3. Results and discussion 
3.1. Effect of cyclooxygenase inhibition 
Recent reports concerning the influence of cyclooxygenase 
inhibitors on the endogenous production of 8-epi-PGF2~ are 
conflicting [1,8,9]. As an integral part of our study, we investi- 
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Fig. 2. Influence of cyclooxgenase inhibitors on the plasma levels of 
esterified 8-epi-PGF2~. Aspirin was used to examine the effect on in vivo 
production of 8-epi-PGF,~ in healthy volunteers (n = 6). Indomethacin 
was used to evaluate x vivo generation of 8-epi-PGF2~ during blood 
collection (n = 6). 
gated the effect of aspirin and indomethacin on the plasma 
levels of 8-epi-PGF2~, both in vivo and ex vivo. 
GS-MS/NICI  analysis revealed no quantifiable levels of free 
8-epi-PGF2~ in the plasma samples before and after aspirin 
treatment (n = 6) at a detection limit of 0.02 nM. However, 
plasma levels (0.02q3.25 nM) of a component with similar re- 
tention time to that of the cyclooxygenase d rived 9~, 11 ~-PGF 2 
were found, regardless of aspirin treatment. In contrast, when 
analysed for total FR-isoprostanes, the plasma samples were 
found to contain 0.10-0.46 nM of esterified 8-epi-PGF2~. As 
shown in Fig. 2, aspirin treatment had no statistically signifi- 
cant effect on the plasma levels of esterified 8-epi-PGF2~ (paired 
Student's t-test, P = 0.39). 
Analysis of plasma samples obtained from indomethacin- 
treated blood (Fig. 2) showed that there was no significant 
effect on the esterified levels of 8-epi-PGF2~ , compared to the 
controls (paired Student's t-test, P = 0.43). In contrast, free 
levels associated with the peak co-eluting with cyclooxygenase- 
derived 9c~,ll~-PGF2was completely suppressed. This indi- 
cated that the component co-eluting with 9c~,ll~-PGF2 was 
generated ex vivo, possibly by platelet activation during the 
preparation of plasma. In agreement with earlier findings by 
Morrow et al. [1], we found that formation of endogenous 
Table 1 
Clinical parameters for control and NIDDM subjects 
Control NIDDM P Normal range 
Size (n) 15 39 - - 
Age (years) 33.4 _+ 3.1 58.9 + 2.3 <0.0001 - 
Fasting glucose (mM) 4.93 + 0.10 12.82 + 0.09 <0.0001 3.3-5.6 
HbA~ (%) 11.17 + 0.37 - 5.0,8.0 
Triglycerides (mM) 1.02 _+ 0.15 3.50 + 0.60 0.0002 0.5-1.8 
Cholesterol (mM) 5.34 + 0.27 5.92 + 1.11 0.61 2.3-6.9 
Data are represented as the mean _+ S.E.M. 
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8-epi-PGF2~ is independent of the cyclooxgenase pathway. 
These results also suggest that blood sampling for the routine 
analysis of 8-epi-PGF2~ can be done without he use of aspirin 
or indomethacin. 
3.2. Plasma 8-epi-PGF2~ as an index o f  oxidative stress 
in vivo 
Plasma from control and NIDDM subjects was analysed for 
the content of free as well as total of 8-epi-PGF2~ as an indica- 
tor of non-enzymatic lipid peroxidation. The analysis revealed 
no measureable levels of free 8-epi-PGF2~. The plasma samples, 
however, had substantial amounts of esterified 8-epi-PGF2~. 
The levels of 8-epi-PGF2~ in individuals with NIDDM (n -- 39) 
varied from 0.49 to 2.16 nM whereas the corresponding levels 
for the controls (n = 16) ranged from 0.02 to 0.63 nM (Fig. 3). 
A representative GC-MS/NICI chromatogram of total F2-iso- 
prostanes i olated from plasma is shown in Fig. 4. Plasma levels 
of esterified 8-epi-PGF2~ among the diabetic subjects were sig- 
nificantly higher than those of the controls (P < 0.0001, Mann- 
Whitney test). Our data reveals that NIDDM is associated with 
increased lipid peroxidation. 
Variation in age among the control and NIDDM individuals 
did not explain the differences in the levels of 8-epi-PGF2~ 
(Pearson's r 2 = 0.0529; P = 0.19 and r 2 = 0.0144; P = 0.21, for 
controls and NIDDM, respectively). Plasma 8-epi-PGF2~ in the 
diabetic group did not correlate with fasting glucose nor HbA,c 
(r 2 = 0.0064; P = 0.31 and r 2 = 0.0009; P -- 0.43, for controls 
and NIDDM, respectively). Moreover, there was no significant 
correlation between plasma 8-epi-PGF2~ and triglycerides or 
total cholesterol in the diabetic group (r 2= 0.0576; P = 0.24 
and r 2 = 0.0169; P = 0.24, respectively). These data suggest that 
increased plasma 8-epi-PGF2~ levels are not functions of hyper- 
glycaemia or hyperlipidaemia. 
F2-isoprostanes may be generated in plasma which has un- 
dergone oxidative degradation during prolonged or improper 
storage. Morrow et al. showed that addition of 0.002% BHT 
inhibited the in vitro formation of F2-isoprostanes in plasma by 
>90%, but did not suppress the levels originally present [1]. In 
this study, SPE and GC-MS analysis of plasma was carried out 
within 2 weeks following sample collection to minimise artefact 
formation during the storage of plasma t -70°C. The absence 
of free 8-epi-PGF2~ in the plasma of control and NIDDM 
individuals, and the fact that esterified plasma 8-epi-PGF2~ 
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Fig. 4. GC-MS/NICI SIM chromatograms of (A) a standard mixture 
of PGF2-1ike compounds; (B) the internal standard PGF2-d4 and 
(C) total (sum of free and esterified) F2-isoprostanes isolated from an 
individual with NIDDM. 
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Fig. 3. Data distribution of total (sum of free and esterified) 8-epi- 
PGF2= levels in plasma from controls (n = 15) and NIDDM (n = 39) 
subjects. 
levels in the two groups of healthy subjects were not statistically 
different (0.34 _+ 0.06 nM (n = 6) vs. 0.28 + 0.04 nM (n = 15); 
P = 0.43) confirm the specificity, precision and reliability of our 
SPE/GC-MS assay. 
In conclusion, we have shown that the GC-MS/NICI analy- 
sis of esterified 8-epi-PGF2~ in plasma provides a specific and 
reliable marker of non-enzymatic peroxidation of arachidonic 
acid in vivo. We have also established that NIDDM is associ- 
ated with increased plasma levels of esterified 8-epi-PGF2~. 
High levels of 8-epi-PGF2= may contribute to the pathophysiol- 
ogy of NIDDM and may be related to long-term vascular 
changes, leading to further complications such as renal failure 
and accelerated atherosclerosis. 
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